There are so many exciting formulas that are both oral and topical that are therapy options for both men’s and women’s hair loss. The gold standard is using Minoxidil in hair growth formulas and the goal is to get the best absorption into the skin possible without causing significant patient side effects. Minoxidil Sulfate is an active metabolite which stimulates hair growth according to many studies. It is the number one product used for Androgenic Alopecia and has been approved by the FDA for this indication.
Finasteride is a 5 alpha-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the androgen responsible for male pattern hair loss (androgenic alopecia). ScriptWorks has many other options for hair growth including Low Dose Oral Minoxidil. There are many other drugs like Tretinoin, Spironolactone, Fluocinonide, and others that doctors can use to enhance each compounded formula.
ScriptWorks’ pharmacists primary job is to research the safety and efficacy of our compounded drug therapies before creating a customized prescription for our patients. Our goal is to create a safe, patient-specific dosage form. Before we filled our first compound for Oral Minoxidil Therapy, we did an in-depth analysis of the safety and side effects of Low Dose Oral Minoxidil. We found quite a few studies (see below) that observed positive results of low dose oral Minoxidil. Since then, more studies have come to the forefront of this therapy. There are side effects that need to be considered and weighed against potential benefits.
A total of 17 studies with 634 patients were evaluated in consideration of oral Minoxidil therapy for hair loss. More Articles:Oral minoxidil treatment for hair loss: A review of efficacy and safety. Randolph M, Tosti A.J Am Acad Dermatol. 2021 Mar;84(3):737-746. doi: 10.1016/j.jaad.2020.06.1009. Epub 2020 Jul 2. PMCID: 32622136
Review.Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series. Beach RA, McDonald KA, Muylaert Barrett B.J Am Acad Dermatol. 2021 Mar;84(3):761-763. doi: 10.1016/j.jaad.2020.10.032. Epub 2020 Oct 22. PMCID: 33098962
No abstract available. Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. Sharma AN, Michelle L, Juhasz M, Muller Ramos P, Atanaskova Mesinkovska N.Int J Dermatol. 2020 Aug;59(8):1013-1019. doi: 10.1111/ijd.14933. Epub 2020 Jun 9. PMCID: 32516434
Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia. Jha AK, Sonthalia S, Zeeshan MD, Vinay K.J Am Acad Dermatol. 2020 Nov;83(5):1491-1493. doi: 10.1016/j.jaad.2020.05.129. Epub 2020 May 31. PMCID: 32492469
Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Hermosa-Gelbard A, Moreno-Arrones OM, Fernandez-Nieto D, Vaño-Galvan S.J Am Acad Dermatol. 2019 Aug;81(2):648-649. doi: 10.1016/j.jaad.2019.04.054. Epub 2019 May 2. PMCID: 31054970
[The therapy of androgenetic alopecia with minoxidil]. Bammel A, Stern R, Sterry W.Dtsch Med Wochenschr. 1993 May 28;118(21):787-9. doi: 10.1055/s-2008-1059391. PMCID: 8504714
Off-Label Use of Topical Minoxidil in Alopecia: A Review.Stoehr JR, Choi JN, Colavincenzo M, Vanderweil S.Am J Clin Dermatol. 2019 Apr;20(2):237-250. doi: 10.1007/s40257-018-0409-y. PMCID: 30604379
Role of Oral Minoxidil in Patterned Hair Loss.Ramírez-Marín HA, Tosti A.Indian Dermatol Online J. 2022 Oct 12;13(6):729-733. doi: 10.4103/idoj.idoj_246_22. eCollection 2022 Nov-Dec. PMCID: free
There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses.Gupta AK, Hall DC, Talukder M, Bamimore MA.Skin Appendage Disord. 2022 Sep;8(5):355-361. doi: 10.1159/000525137.
In topical and compounded regimens, Finasteride remains a key option for targeting DHT-driven hair loss, while Minoxidil-based formulations continue to be the foundational element for hair growth stimulation. The collaboration between clinicians and compounding pharmacists allows for tailored dosing strategies, solvent systems, and penetration enhancers to optimize efficacy while monitoring for adverse effects.
There are several practical considerations for a compounding pharmacy when addressing topical finasteride and combination therapies. First, patient-specific factors such as age, sex, hormonal status, and comorbidities influence formulation choices and risk profiles. Second, the selection of vehicles, penetration enhancers, and carrier systems can affect skin absorption and tolerability. Third, thorough patient education on potential side effects, monitoring plans, and adherence strategies is essential to maximize therapeutic benefit and safety. Finally, ongoing review of emerging literature and clinical experience helps update compounded regimens to align with best practices.
In sum, topical finasteride and related compounded therapies present a promising, personalized approach to hair loss management. By aligning evidence on minoxidil absorption and the anti-DHT action of finasteride with careful formulation science, compounding pharmacies can deliver effective, patient-centered options for both men and women seeking to address androgenetic alopecia and related conditions.
ORAL VS. TOPICAL FINASTERIDE? 💊 A Doctor’s Honest Opinion!
| Therapy | Key Mechanism | Notes |
|---|---|---|
| Topical Minoxidil | Stimulates hair follicles; increases blood flow | FDA approved for AGA; absorption optimization important |
| Oral Minoxidil (low-dose) | Vasodilation; systemic hair growth effects | Multiple studies on efficacy and safety; dose-dependent |
| Topical Finasteride | Inhibits 5-alpha-reductase; reduces DHT at scalp | Used in compounding for men and women; potential systemic exposure |
| Combination/Other agents | Tretinoin, Spironolactone, Fluocinonide | Adjuncts to enhance penetration and anti-androgenic effects |
tags: #topical #finasteride #compounding #pharmacy